Fig 5. MTX does not modulate mRNA expression of cPLA2 enzyme involved in AA-release for PGE2 synthesis in HSF.
A) cPLA2 mRNA levels from HSF infected by CHIKV at MOI 10−1 and 10−4 or stimulated by PIC 100μg/mL and 10μg/mL for 6h and 24h in the absence and presence of MTX 1μM treatment as assessed by qRT-PCR. B) mRNA levels of cPLA2 were assessed by qRT-PCR in HSF exposed to IFNβ at the concentration of 1000U/mL and 100U/ml and treated or not with MTX 1μM. HSF were also stimulated by IL-1β 1ng/mL and TNFα 10ng/mL in the absence and presence of DXM 1μM treatment to assess cPLA2 mRNA levels. All experiments were done in triplicates. Results are expressed as mean ± standard error and presented as normalized fold increase vs control. *: p-values ≤ 0.05, **: p-values ≤ 0.01 and ***: p-values ≤ 0.001 represent significant difference from controls by one-way ANOVA followed by the Bonferroni’s test analysis. #: p-values ≤ 0.05, ##: p-values ≤ 0.01 signifies statistical difference of samples treated with the drug (MTX or DXM) compared to untreated samples under the different stimulatory conditions by Student’s t-test.